HIV co-receptor identification: Good or bad news for drug discovery?

Current Opinion in Immunology

Volumn 9, Issue 5, 1997, Pages 628-630

  Landau, Nathaniel R ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR; PROTEINASE INHIBITOR; RECEPTOR BLOCKING AGENT; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; NONHUMAN; VIRUS PATHOGENESIS;

EID: 0030724594     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80040-4     Document Type: Editorial

References (12)

1. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 9:1997;551-562.
2. Deng HK, Unumatz D, Kewal Ramani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 388:1997;296-300.
3. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 32:1997;194-209.
4. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science. 277:1997;959-965.
5. Speck RF, Wehrly K, Platt EJ, Atchinson RE, Charo IF, Kabat D, Chesebro B, Goldsmith BA. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol. 71:1997;7136-7139.
6. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx D, Sheppard HW. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med. 3:1997;338-340.
7. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11:1997;305-310.
8. Connor RI, Sheridan KS, Ceradini D, Choe S, Landau NR. Change in co-receptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med. 185:1997;621-628.
9. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton D, Ho D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 69:1995;101-109.
10. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis. 169:1994;54-59.
11. Zolla-Pazner S. Mechanisms contributing to the neutralization of HIV-1. Immunol Lett. 51:1996;81-93.
12. Daar E, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary HIV-1 isolates. Proc Natl Acad Sci USA. 87:1990;6574-6578.